BENTONVILLE, Arkansas, Nov. 3, 2021 /PRNewswire/ — Glucose Health, Inc. (OTC: “GLUC”) (“Company”) is pleased to highlight key financial information detailed in its Fiscal 2021 Third Quarter Report, for the period ending September 30, 2021, posted at OTCMarkets.com.
- Nine Month Fiscal 2021 Revenue of $759,498 vs. $361,256 for Nine Month Fiscal 2020 – an increase of 110%
- Q3 Fiscal 2021 Revenue of $234,930 vs. $126,504 for Q3 Fiscal 2020 – an increase of 86%
- Nine Month Fiscal 2021 Gross Profit of $279,748 vs. $165,265 for YTD Fiscal 2020 – an increase of 69%
- Q3 Fiscal 2021 Gross Profit of $85,714 vs. $68,379 for Q3 Fiscal 2020 – an increase of 25%
GLUCODOWN® continues to enjoy increasingly popularity among consumers as evidenced by outstanding sales and reviews at Amazon. In total, many thousands of reviews have been published at Amazon, with seven of eight flavors of GLUCODOWN® receiving 4.5-star ratings. Additionally, all double-packs receive 4.5 and 5 star reviews. Customers most often identify health benefits and delicious taste, as the reasons for satisfaction with purchasing GLUCODOWN®.
Additionally, during this quarter, the Glucose Health, Inc. will provide a progress report regarding its enterprise value enhancing, intellectual property initiative, first referenced in the Company’s January 4, 2021, press release.
About Glucose Health, Inc. (OTC: GLUC)
With a focus on creating delicious beverages nutritionally appropriate1 for the nation’s 100+ million2 pre and Type-2 diabetics, Glucose Health, Inc., the manufacturer of GLUCODOWN®, is uniquely positioned among all emerging beverage companies in America. Introduced in the third quarter of 2018, the GLUCODOWN® brand has established itself as the market leader for an entirely new category – functional, diabetic friendly, beverages. Glucose Health, Inc. is a publicly traded company with the ticker symbol OTC: GLUC.
To buy GLUCODOWN® visit our Amazon Store at www.amazon.com/glucodown
Like us on Facebook at www.facebook.com/glucodown
For more GLUC information visit www.glucosehealthinc.com
- For citations visit www.glucodown.com/clinical-data
- National Diabetes Statistics Review, 2020; Centers for Disease Control and Prevention, Department of Health and Human Services
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and while Glucose Health, Inc. is not subject to the 1934 Securities and Exchange Act, contains forward-looking statements within the meaning Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential, “possible,” “probable, “believes,” “seeks,” “may, “will, “should,” “could” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
Glucose Health, Inc.
SOURCE Glucose Health, Inc.